INTS (Intensity Therapeutics) Current Accrued Expense: $0.93 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INTS Intensity Therapeutics Inc INTS
32 GF Score
Price $4.21
! 1 Warning Sign
View Full Analysis

What is Intensity Therapeutics Current Accrued Expense?

Intensity Therapeutics INTS -0.24% 32 Current Accrued Expense is $0.93 Mil as of Jun. 2026. GuruFocus rates INTS with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Intensity Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.93 Mil.

Intensity Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($0.73 Mil) to Mar. 2026 ($0.66 Mil) but then increased from Mar. 2026 ($0.66 Mil) to Jun. 2026 ($0.93 Mil).

Intensity Therapeutics's annual Current Accrued Expense declined from Dec. 2023 ($0.50 Mil) to Dec. 2024 ($0.45 Mil) but then increased from Dec. 2024 ($0.45 Mil) to Dec. 2025 ($0.73 Mil).

Intensity Therapeutics Current Accrued Expense Related Terms

Intensity Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Intensity Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intensity Therapeutics Current Accrued Expense Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 1.35 1.72 0.50 0.45 0.73

Intensity Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.55 0.73 0.66 0.93
INTS
32GF Score
Intensity Therapeutics Inc INTS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intensity Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.93 Mil mean?
Intensity Therapeutics (INTS) has a Current Accrued Expense of $0.93 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Intensity Therapeutics and its competitors.
Is Intensity Therapeutics' Current Accrued Expense too high?
Intensity Therapeutics' current Current Accrued Expense is $0.93 Mil. Overall, Intensity Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' Current Accrued Expense compare to ICU and GTBP?
Intensity Therapeutics' Current Accrued Expense of $0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Intensity Therapeutics and its competitors. Intensity Therapeutics's current Current Accrued Expense is $0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current Current Accrued Expense of $0.93 Mil. The current Current Accrued Expense is $0.93 Mil. Intensity Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current Current Accrued Expense is $0.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intensity Therapeutics Business Description

Address 1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
32GF Score

Get the complete analysis for INTS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.21
Price